Scarica l'app Stockscreener
8.76
2.12%
-0.19
Pre-mercato:
8.83
0.07
+0.80%
Precedente Chiudi:
$8.95
Aprire:
$8.87
Volume 24 ore:
1.21M
Relative Volume:
1.10
Capitalizzazione di mercato:
$762.21M
Reddito:
-
Utile/perdita netta:
$-106.81M
Rapporto P/E:
-2.6452
EPS:
-3.3117
Flusso di cassa netto:
$-8.40M
1 W Prestazione:
+3.18%
1M Prestazione:
+2.58%
6M Prestazione:
-35.35%
1 anno Prestazione:
-40.45%
Intervallo 1D:
$8.50
$8.895
Intervallo di 1 settimana:
$8.32
$9.035
Portata 52W:
$5.1501
$16.81
Immunome Inc Stock (IMNM) Company Profile
Nome
Immunome Inc
Settore
Industria
Telefono
610-321-3700
Indirizzo
18702 N. CREEK PARKWAY, BOTHELL
Confronta IMNM con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IMNM
Immunome Inc
|
8.76 | 738.73M | 0 | -106.81M | -8.40M | -3.3117 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Immunome Inc Stock (IMNM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-02 | Iniziato | Lake Street | Buy |
| 2024-11-08 | Iniziato | Stephens | Overweight |
| 2024-05-31 | Iniziato | Piper Sandler | Overweight |
| 2024-04-30 | Iniziato | JP Morgan | Overweight |
| 2024-04-15 | Iniziato | Guggenheim | Buy |
| 2024-01-29 | Iniziato | Leerink Partners | Outperform |
| 2023-12-19 | Iniziato | Wedbush | Outperform |
| 2021-10-29 | Iniziato | Cantor Fitzgerald | Overweight |
Mostra tutto
Immunome Inc Borsa (IMNM) Ultime notizie
Deutsche Bank AG Has $489,000 Stock Holdings in Immunome, Inc. (NASDAQ:IMNM) - Defense World
Wall Street Analysts Think Immunome (IMNM) Could Surge 188.57%: Read This Before Placing a Bet - MSN
Immunome, Inc. (NASDAQ:IMNM) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
(IMNM) Trading Report - news.stocktradersdaily.com
Immunome to Present at Upcoming Investor Conferences - BioSpace
Cancer Therapy Developer Immunome Set for TD Cowen and Goldman Sachs Healthcare Conferences - Stock Titan
Immunome, Inc. (NASDAQ:IMNM) Shares Acquired by Northern Trust Corp - Defense World
Immunome, Inc. Reports Q1 2025 Financial Results - TipRanks
Immunome stock rating cut to Hold by Boral Capital - Investing.com Nigeria
Immunome, Inc. (IMNM) Reports Q1 Loss, Tops Revenue Estimates - MSN
Leerink Partnrs Has Strong Estimate for Immunome Q2 Earnings - Defense World
Voya Investment Management LLC Has $166,000 Stock Position in Immunome, Inc. (NASDAQ:IMNM) - Defense World
All You Need to Know About Immunome (IMNM) Rating Upgrade to Buy - MSN
Immunome (NASDAQ:IMNM) Shares Gap Up Following Earnings Beat - Defense World
Immunome (IMNM) Financial Update and Clinical Progress in Q1 202 - GuruFocus
Wedbush Adjusts Price Target on Immunome to $21 From $33, Maintains Outperform Rating - marketscreener.com
(IMNM) Investment Report - news.stocktradersdaily.com
Immunome Reports First Quarter 2025 Financial Results and Provides Business Update - BioSpace
Immunome Inc (IMNM) Q1 2025 Earnings: EPS Loss of $0.52 Beats Es - GuruFocus
Immunome Q1 Income From Operations USD -44.636 Million - marketscreener.com
Immunome Expands Share Reserve in Inducement Plan - TipRanks
Immunome Reports First Quarter 2025 Financial Results and Provides Business Update | IMNM Stock News - GuruFocus
Raymond James Financial Inc. Makes New $274,000 Investment in Immunome, Inc. (NASDAQ:IMNM) - Defense World
Wall Street Analysts Believe Immunome (IMNM) Could Rally 249.93%: Here's is How to Trade - MSN
Immunome (IMNM) Expected to Announce Earnings on Tuesday - Defense World
MetLife Investment Management LLC Purchases 5,354 Shares of Immunome, Inc. (NASDAQ:IMNM) - Defense World
Immunome, Inc. (NASDAQ:IMNM) Shares Purchased by Wells Fargo & Company MN - Defense World
Invesco Ltd. Cuts Stock Holdings in Immunome, Inc. (NASDAQ:IMNM) - Defense World
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 2, 2025 - BioSpace
Brokerages Set Immunome, Inc. (NASDAQ:IMNM) Price Target at $25.33 - Defense World
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 563 - GuruFocus
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | IMNM Stock News - GuruFocus
(IMNM) Investment Analysis and Advice - news.stocktradersdaily.com
Taking on analysts’ expectations and winning: Immunome Inc (IMNM) - Sete News
Immunome Inc [IMNM] stock for 60,684 USD was acquired by BIENAIME JEAN JACQUES - knoxdaily.com
Legal & General Group Plc Sells 8,796 Shares of Immunome, Inc. (NASDAQ:IMNM) - Defense World
Immunome (IMNM) Trades at Significant Discount, Piper Sandler An - GuruFocus
Piper says SpringWorks deal suggests Immunome’s varegacestat ‘undervalued’ - TipRanks
Was there any good news for Immunome Inc (IMNM) stock in the last session? - uspostnews.com
Immunome Inc Azioni (IMNM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Immunome Inc Azioni (IMNM) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| BIENAIME JEAN JACQUES | Director |
Mar 25 '25 |
Buy |
7.78 |
7,800 |
60,684 |
31,415 |
| SIEGALL CLAY B | President and CEO |
Mar 26 '25 |
Buy |
7.29 |
137,100 |
999,459 |
806,736 |
| BIENAIME JEAN JACQUES | Director |
Mar 24 '25 |
Buy |
8.21 |
7,000 |
57,470 |
23,615 |
| Tsai Philip | Chief Technology Officer |
Mar 24 '25 |
Buy |
8.42 |
12,300 |
103,566 |
33,300 |
| SIEGALL CLAY B | President and CEO |
Jan 31 '25 |
Buy |
7.75 |
150,000 |
1,162,500 |
669,636 |
| SIEGALL CLAY B | President and CEO |
Nov 21 '24 |
Buy |
9.54 |
66,057 |
630,263 |
485,693 |
| SIEGALL CLAY B | President and CEO |
Nov 22 '24 |
Buy |
9.78 |
33,943 |
331,918 |
519,636 |
| Lechleider Robert | Chief Medical Officer |
Nov 21 '24 |
Buy |
9.48 |
15,805 |
149,800 |
15,805 |
| Tsai Philip | Chief Technology Officer |
Nov 21 '24 |
Buy |
9.43 |
21,000 |
198,030 |
21,000 |
| Rosett Max | Chief Financial Officer |
Sep 19 '24 |
Option Exercise |
1.05 |
42,000 |
44,100 |
61,856 |
1.89%
3.74%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):